Author

Nina Benachour

Observed name: N. Benachour

Institutions: Johnson & Johnson (United States), Janssen (Belgium)

Observed institutions: Johnson & Johnson (United States), Janssen (Belgium)

OpenAlex ID: A5113348786

Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial

2026 · Hermann Einsele, Jesús San-Miguel, et al. · The Lancet Oncology · 52

OA-65 Overall Survival (OS) With Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care (SoC) in Lenalidomide (Len)-Refractory Multiple Myeloma (MM): Phase 3 CARTITUDE-4 Study Update

2024 · María-Victoria Mateos, Jesús San-Miguel, et al. · Clinical Lymphoma Myeloma & Leukemia · 30

Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1-3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial

2024 · Rakesh Popat, Albert Oriol, et al. · Blood · 14

Effectiveness of bridging therapy corresponds to improved outcomes after ciltacabtagene autoleucel: Phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma

2025 · Binod Dhakal, Shinsuke Iida, et al. · Blood · 10

PDF

Ciltacabtagene autoleucel (cilta-cel) vs standard of care (SOC) in patients (pts) with relapsed/refractory multiple myeloma (MM): CARTITUDE-4 survival subgroup analyses.

2025 · Surbhi Sidana, Joaquin Martinez-Lopez, et al. · Journal of Clinical Oncology · 7

PDF

Long-term progression-free survival benefit with ciltacabtagene autoleucel in standard-risk relapsed / refractory multiple myeloma

2025 · Luciano Costa, Albert Oriol, et al. · Blood · 5

P-005 Effectiveness of Bridging Therapy Corresponds to Improved Outcomes After Receiving CAR-T Therapy: Phase 3 CARTITUDE-4 Study of Patients With Relapsed, Lenalidomide-Refractory Multiple Myeloma

2024 · Sébastien Anguille, Xavier Leleu, et al. · Clinical Lymphoma Myeloma & Leukemia · 5

MM-522 Effectiveness of Bridging Therapy Corresponds to Improved Outcomes After Receiving CAR-T Therapy: Phase 3 CARTITUDE-4 Study of Patients With Relapsed, Lenalidomide-Refractory Multiple Myeloma

2024 · Yi Lin, Xavier Leleu, et al. · Clinical Lymphoma Myeloma & Leukemia · 3

Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1–3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial

2025 · Rakesh Popat, Albert Oriol, et al. · Transplantation and Cellular Therapy · 2

Long-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial

2024 · Noffar Bar, Roberto Mina, et al. · Blood · 2

PDF

POSTER: MM-1070 Ciltacabtagene Autoleucel vs Standard of Care in Patients With Relapsed/Refractory Multiple Myeloma: CARTITUDE-4 Survival Subgroup Analyses

2025 · Surbhi Sidana, Joaquín Martínez-López, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

MM-1070: Ciltacabtagene Autoleucel vs Standard of Care in Patients With Relapsed/Refractory Multiple Myeloma: CARTITUDE-4 Survival Subgroup Analyses

2025 · Surbhi Sidana, Joaquín Martínez-López, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

P-057 Comparative Efficacy of Cilta-Cel vs Approved Comparator Treatments for Patients With Relapsed/Refractory Multiple Myeloma With 1–3 Prior Lines of Therapy: A Network Meta-Analysis

2024 · Roberto Mina, Abdullah Khan, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

Effectiveness of Bridging Therapy Corresponds to Improved Outcomes After Receiving CAR-T Therapy: Phase 3 CARTITUDE-4 Study of Patients With Relapsed, Lenalidomide-Refractory Multiple Myeloma

2024 · Yi Lin, Xavier Leleu, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

Ciltacabtagene Autoleucel vs Standard of Care in Lenalidomide-Refractory Multiple Myeloma: Phase 3 CARTITUDE-4 Subgroup Analysis by Cytogenetic Risk

2024 · Roberto Mina, Binod Dhakal, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

MM-567 Ciltacabtagene Autoleucel vs Standard of Care in Lenalidomide-Refractory Multiple Myeloma: Phase 3 CARTITUDE-4 Subgroup Analysis by Cytogenetic Risk

2024 · Roberto Mina, Binod Dhakal, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

MM-770: Ciltacabtagene Autoleucel in Lenalidomide-Refractory Multiple Myeloma Responding to Bridging Therapy: CARTITUDE-4 Cytogenetic Subgroup Analysis

2026 · Roberto Mina, Niels WCJ van de Donk, et al. · Clinical Lymphoma Myeloma & Leukemia

POSTER: MM-770: Ciltacabtagene Autoleucel in Lenalidomide-Refractory Multiple Myeloma Responding to Bridging Therapy: CARTITUDE-4 Cytogenetic Subgroup Analysis

2026 · Roberto Mina, Niels Wcj van de Donk, et al. · Clinical Lymphoma Myeloma & Leukemia

Ciltacabtagene autoleucel in lenalidomide-refractory multiple myeloma responding to bridging therapy: CARTITUDE-4 cytogenetic subgroup analysis.

2026 · Roberto Mina, Niels W.C.J. van de Donk, et al. · Journal of Clinical Oncology

P36 | Effectiveness of Bridging Therapy Corresponds to Improved Outcomes After Ciltacabtagene Autoleucel: Phase 3 Cartitude-4 Study of Patients With Relapsed, Lenalidomide-refractory Multiple Myeloma

2026 · E. Zamagni, B. Dhakal, et al. · Haematologica

PDF

P48 | Long-term Progression-free Survival Benefit With Ciltacabtagene Autoleucel in Standard-risk Relapsed/refractory Multiple Myeloma

2026 · D. Dytfeld, L.J. Costa, et al. · Haematologica

PDF

Long-Term Progression-Free Survival Benefit with Ciltacabtagene Autoleucel in Standard-Risk relapsed/refractory Multiple Myeloma

2026 · Luciano J. Costa, Albert Oriol, et al. · Transplantation and Cellular Therapy

Effectiveness of Bridging Therapy Corresponds to Improved Outcomes after Ciltacabtagene Autoleucel: Phase 3 CARTITUDE-4 Study of Patients with Relapsed, Lenalidomide-Refractory Multiple Myeloma

2026 · Binod Dhakal, Shinsuke Iida, et al. · Transplantation and Cellular Therapy

2025 · Noffar Bar, Roberto Mina, et al. · Transplantation and Cellular Therapy

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Isatuximab, Carfilzomib and Dexamethasone in the Treatment of Patients with Lenalidomide-Refractory Multiple Myeloma with 1-3 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

2024 · Roberto Mina, Paolo Corradini, et al. · Blood

PDF

Works count: 26

Citation count: 136

H-index: 5

I10-index: 4